Trial Parameters
Brief Summary
A Clinical Evaluation of AMJ-401 in the Treatment of Subjects with Ischemic Heart Disease in Japan
Eligibility Criteria
Inclusion Criteria 1. Subject must be at least 18 years of age. 2. Subject or a legally authorized representative must be able to provide written Informed Consent prior to any study related procedure, per site requirements. 3. Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia, unstable angina, acute myocardial infarction) suitable for elective PCI. 4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery. 5. Subject must be able to take dual antiplatelet therapy (DAPT) for minimum of 12 months following the index procedure and anticoagulants prior/during the index procedure, and the subject has no known allergic reaction, hypersensitivity or contraindication to aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine or heparin. 6. Female subjects of childbearing potential must not be pregnant\* at screening and do not plan pregnancy for at least 12 months following the index procedure. \* Female subjects of child-